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Key Clinical Message
Diabetes in neonates is a monogenetic disease and genetic analysis is warranted
to allow best treatment, prognosis, and genetic counseling. Transcription factor
mutations may have a variable expression and different organs may be
involved.
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Introduction
Children with diabetes mellitus requiring permanent insu-
lin treatment from the neonatal period onwards need to
be offered genetic screening in order to identify single-
gene mutations. A precise genetic diagnosis may not only
influence treatment, prognosis and genetic counseling but
also provides further insight in the beta cell function and
pancreas development. We describe a neonate presenting
with intrauterine growth retardation, pancreatic endocrine
and exocrine dysfunction as well as severe cardiac malfor-
mations. Exome sequencing revealed a novel de novo het-
erozygous frameshift mutation (c.968dupA; p.Tyr323 fs)
in exon 2 of GATA6, leading to a premature stop signal
and a truncated protein. Although GATA6 has been
reported in relationship with neonatal diabetes, pancreatic
aplasia, and cardiac malformations, the cardiac malforma-
tions are more often reported in relationship with
GATA4, sharing a high degree of homology with GATA6.
In this case, the mutation was only identified in GATA6.
This finding expands the spectrum of mutations in
GATA6 linked to pancreatic dysfunction and the cardiac
malformations suggesting, furthermore, the critical role of
GATA6 in pancreas and cardiac organogenesis in the
human.
Although type 1 diabetes mellitus, or auto immune
diabetes, remains the most frequent form of diabetes in
childhood, this diagnosis needs to be carefully reevaluated
when hyperglycemia is associated either with morbid
obesity in the adolescent age (type 2 diabetes mellitus) or
with a very early onset (before 6 months of life) and/or
with a highly positive family history (monogenic forms of
diabetes including neonatal diabetes or mitochondrial
diabetes) [1–3].
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Contrary to the classical multifactorial type 1 and type
2 diabetes mellitus, the monogenic forms result from
mutations in single gene. These single-gene mutations
have contributed to our understanding of the insulin
secretion, insulin effect and more recently to our knowl-
edge on pancreatic development. Besides, they have thera-
peutic and prognostic implications as in some situations
insulin treatment can be replaced by oral drug therapy
and better metabolic outcome.
Neonatal diabetes can be permanent (hyperglycemia
starts within the first few months (<6 months) after birth
and does not resolve over time) or transient (treatment
can be stopped after 3–6 months). When an abnormality
is detected in the imprinted region of chromosome 6, this
suggests a transient form of neonatal diabetes, whereas in
the permanent form, the role of ATP sensitive potassium
channels (KCNJ11 [MIM 600937] and ABCC8 [MIM
600509]) in the beta cell has been extensively described
[4]. More recently, some gene mutations in transcription
factors (TFs) involved in pancreatic development (leading
to pancreas agenesis or hypoplasia) have been identified
playing a role in the development of neonatal diabetes
including PDX1 (MIM 600733) [5], PTF1A (MIM
607194) [6], and GATA4 (MIM 600576) [7]. Although
many cases remain unresolved, it remains relevant to
screen for a genetic form of diabetes mellitus, if the child
is diagnosed with diabetes before the age of 7–8 months.
In a recent review, 171 out of 795 cases with unknown
origin of their NDM were screened for a GATA6 muta-
tion. The screening showed in 29 cases, a mutation in
relationship with different clinical phenotypes [8].This
genetic analysis should not be limited to those with a
positive family history as de novo events might arise.
Disease treatment, long-term outcome, as well as genetic
counseling may be influenced by this issue.
We report here a novel mutation in exon 2 of GATA6
(MIM 601656) leading to permanent diabetes, exogenous
pancreas insufficiency, and congenital heart defects.
The Regional Ethical Committee for Medical Research
approved this study, which was performed according to
the Helsinki Declaration. We obtained written informed
consent from the parents for genetic testing.
The boy is the first child of healthy parents. There is
no diabetes known in either families. He was born small
for gestational age (38 6/7 weeks) without any identified
maternal cause and a normal pregnancy. His bodyweight
was 1560 g, his height 38 cm and head circumference
27.5 cm and an APGAR score of 8 (1 min) 9 (5 min)
and 9 (10 min). A small placenta was found without
other abnormalities. Shortly after arrival in the neonatal
ward, the child developed hyperglycemia without any
infections or other explanation and with low insulin levels
(glucose: 290 mg/dL (16.1 mmol/L); insulin: 2.9 mU/L).
Further analysis (ultrasound) revealed only the pancreas
head and tail but no body, abnormal mesenteric veins,
without further malrotation, no brain abnormalities, but
cardiac malformations (large muscular as well as a peri-
membraneous ventricular septal defect, an atrial septal
defect (MIM 108800), valvular (MIM 265500), and supra-
valvular pulmonary stenosis). Further analysis revealed
very low elastase level in the feces (<50 mcg/g) suggesting
an exogenous pancreatic insufficiency as well. Intravenous
insulin treatment was started and within the first few
weeks replaced by continuous subcutaneous insulin infu-
sion ensuring as physiological as possible administration
of insulin and fast return home. Within his first year of
life, corrective cardiac surgery was performed. For the
exogenous pancreatic insufficiency, enzyme replacement
was given. Insulin treatment remained necessary, confirm-
ing the diagnosis of permanent neonatal diabetes mellitus
(MIM 606176). His current development is excellent and
he has achieved all psychomotor development milestones
as well as growth within the normal reference range at
the age of 2 years. His metabolic control with continuous
subcutaneous insulin infusion is good, without major
acute complications.
Taking the intrauterine growth retardation, pancreatic
endocrine and exocrine dysfunction, and cardiac malfor-
mations into account, genetic testing was proposed for the
child and both his parents. Whole exome sequencing in
both the proband and parents was performed at Hudson
Alpha Institute for Biotechnology (Huntsville, AL) using
Roche–NimbleGen Sequence Capture EZ Exome v2 kit
(Roche NimbleGen, Inc., Madison, WI) and paired-end
100nt sequencing on the Illumina HiSeq [9–13].
Standard whole exome sequencing analysis [13] did not
reveal any likely causative mutation in the child. We,
therefore, next identified regions of low coverage among
a set of genes previously defined as potential monogenic
diabetes candidate genes [13]. In a region of poor cover-
age in exon 2 of GATA6, we detected one single read in
the proband with a 1-bp insertion predicted to encode a
frameshift of the protein at residue 323 (c.968dupA;
p.Tyr323 fs). Sanger sequencing confirmed the presence
of a de novo heterozygous mutation in the child with
absence of the mutation in both parents (Fig. 1). This de
novo mutation has not been reported previously.
Recent studies by Bonnefond [14] and Yorifuji [15]
suggest a high degree of variability in the clinical manifes-
tation of GATA6 haploinsufficiency. The great diversity in
the phenotypic spectrum between carriers of GATA6-
mutations suggests the existence of modifier genes. Two
recent studies in mice have shown that double knockout
of Gata4 and Gata6 [16, 17] caused complete pancreatic
agenesis in contrast to single-gene knockout Gata4 or
Gata6 that did not significantly affect normal pancreas
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morphogenesis. Therefore, we searched for potentially
functional modifier mutations in putative candidate genes
such as GATA4 and GATA5 (MIM 611496) but found no
obvious candidate mutations.
The GATA family of transcription factors represents a
group of evolutionary conserved zinc finger TFs involved
in development and differentiation of eukaryotic organ-
isms. In vertebrates, this family of TFs is split into two
subgroups encompassing in total six members including
the hematopietic (GATA1/2/3) and cardiac groups
(GATA4/5/6) [18]. GATA4/5/6 are expressed in tissues of
endodermal and mesodermal origin [19] including among
others gut, lung, heart, and pancreas. GATA6 shows a
high temporal and functional overlap with GATA4 during
cardiac development [20]. This TF includes an N-terminal
transcription activator domain as well as two tandem
GATA zinc fingers acting together as DNA-binding
domain.
Currently, the Human Gene Mutation Database (Pro-
fessional release 2012.3) contains 25 clinically relevant
mutations for GATA6. Different studies have related
GATA6 mutations to congenital cardiac defects including
ventricular septal defect [21, 22], tetralogy of Fallot [20,
23], and persistent truncus arteriosus [24]. Furthermore,
two recent studies were able to delineate the implication
of heterozygous mutations in the coding sequence of
GATA6 in pancreatic agenesis in conjunction with cardiac
defects based on whole exome sequencing of individuals
[25, 26].
Interestingly, on the basis of the analysis of the whole
exome of two nonconsanguineous sisters, Bonnefond and
collaborators [14] identified a truncating mutation in
GATA6 that has a distinct phenotypic penetrance on the
level of pancreatic development (pancreatic agenesis/
hypoplasia) in the two sisters, while both sisters show
heart anomalies. Allen and collaborators [25] revealed in
their study a high proportion of GATA6 mutations (15
individuals) in a panel of 27 patients with pancreatic
agenesis. In addition, among these individuals, 14 of 15
showed cardiac malformations.
In this study, we report a novel de novo heterozygous
mutation (c.968dupA; p.Tyr323 fs) in the coding
sequence of GATA6 located in the N-terminal transcrip-
tion activator domain of GATA6 resulting in a truncated
protein. The individual is affected by cardiac malforma-
tions and pancreatic hypoplasia requiring insulin treat-
ment and enzyme replacement therapy. These
observations are in the same phenotypic range as reported
in recent studies [14, 25].
Moreover, the clinical features we observe in this case
confirm the relevance of GATA6 haploinsufficiency in
human for pancreatic developmental perturbations. It is
well-known that haploinsufficiency of TF genes is not
uncommon in human developmental disorders [26].
Furthermore, these authors suggested that the increased
probability for such TF genes to show functionally rele-
vant fluctuations in their RNA levels might not be buf-
fered sufficiently by the expression of only one healthy
allele.
The clinical relevance of the de novo mutation
described in this study that leads to a premature termina-
tion codon has not been described so far. Even though
this study does not focus on a functional study of the
observed insertion, we think that the mutation we observe
here, is likely to have a functional impact comparable to
those reported by Allen et al. [25] and Bonnefond et al.
[14]. Genetic screening of children developing diabetes
mellitus before 6 months has increased our knowledge on
the pathophysiology of insulin secretion and insulin
action and should become current practice in all these
children, ensuring personalized medical care.
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Figure 1. De novo mutation in exon 2 of GATA6 detected in the
proband. (A) An IGV snapshot of a region in exon 2 of GATA6, which
was poorly covered in whole exome sequencing (with 2, 0, and 1
reads in the proband, mother and father, respectively) and shows a 1-
bp insertion (arrow, Ins A) in one single read in the proband. (B)
Chromatograms of Sanger sequencing show the insertion in
heterozygous status (arrow, Ins A) in the proband that is not found in
the parents.
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Web Resources
The URLs for data presented herein are as follows: Online
Mendelian Inheritance in Man (OMIM), http://www.
omim.org.
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